FutureMeds, an independent European site monitoring organization with a developing network of compromised study sites, recently introduced a new pilot assignment, FutureMeds go!to new treatments.
FutureMeds va! was created in response to the recent and existing physical emergency brought on by the pandemic. Their project is to reach others who find more complicated and expensive treatments and give traditionally overlooked communities access to new treatments.
According to initial estimates from FutureMeds, a single cell unit will be able to care for and assist more than 15,000 patients each year. The vision of FutureMeds go! and physician communities. commented Dr. Piotr Rozpondek, MD, PhD, Managing Director of FutureMeds Poland.
Continuing the trend established during the pandemic, FutureMeds is actively reorienting the clinical studies it conducts towards decentralized clinical trials.
Decentralized clinical trial elements, such as FutureMeds go! Mobile, are an effective technique to overcome the demanding situations of classic trials, such as patient awareness, geographical distance from sites, time constraints caused by the duration of the examination and the number of clinical visits. They have benefits for expanding trial efficiency: they can reduce costs, shorten trial times, and enable faster and more effective patient recruitment while achieving better patient engagement.
“There are wonderful opportunities for our developing network of committed study sites on FutureMeds to put learnings from the pandemic into practice,” said Radoslaw Janiak, CEO of FutureMeds. how their rapid changes can be replicated in healing spaces such as downtown diseases, diabetes, and other high-impact conditions. Using learnings, we are now on track to increase exam times through carefully used decentralized and hybrid methodologies that can definitely have an effect on patients’ access to cutting-edge medicines and the industry as a whole.
Reproducing and applying classes of COVID-19 vaccination systems can cause lasting transformations in clinical trials and deliver life-changing treatments faster than ever before.
FutureMeds continues to expand its diversity of patient-centered sponsors to help and CROs start trials faster, collect accurate data, and protect exam timelines.
FutureMeds is a fast-growing, independent monitoring organization that supports pharmaceutical companies, sponsors and CROs and contributes to studies to locate effective remedies and medications for all patients who want them.
FutureMeds’ committed study site teams aim to increase examination times, streamline processes, reduce costs and data quality to help increase patient access to new treatments.
Through acquisitions and a patient experience strategy, the company has developed qualified patient teams across Europe that enable faster patient enrollment and better retention and support for more accurate results.
For more information, visit futuremeds. com or connect with us on LinkedIn.